Time to get long GILD
Gilled is an extremely strong company fundamentally with huge earnings growth. Stock was hid with uncertainty with competition or ABBY but their new Hep C drugs should still control 80-90% of market share. Also the retracement off the recent high has found solid support at the $100 level. The stock looks ready for a move higher
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。